<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363090</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000491451</org_study_id>
    <secondary_id>TSRCC-164-2006</secondary_id>
    <nct_id>NCT00363090</nct_id>
  </id_info>
  <brief_title>Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toronto Sunnybrook Regional Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such&#xD;
      as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop&#xD;
      the growth of cancer cells, either by killing the cells or by stopping them from growing.&#xD;
      Giving alemtuzumab together with combination chemotherapy may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of alemtuzumab when&#xD;
      given together with combination chemotherapy and to see how well they work in treating&#xD;
      patients with newly diagnosed aggressive stage II, stage III, or stage IV T-cell&#xD;
      non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Establish the safety and dose-limiting toxicities of alemtuzumab in combination with&#xD;
           cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP)&#xD;
           chemotherapy in patients with newly diagnosed, stage II-IV aggressive peripheral T-cell&#xD;
           non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Measure the pharmacokinetics of alemtuzumab using different subcutaneous doses and&#xD;
           schedules to determine the dose with the highest achievable drug levels with acceptable&#xD;
           toxicities worthy of further investigation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the efficacy of alemtuzumab in combination with CHOP chemotherapy using&#xD;
           escalating doses and 2 different drug schedules, as defined by overall response rate,&#xD;
           progression-free survival, and overall survival.&#xD;
&#xD;
        -  Measure the effects of this regimen on T-cell reconstitution and cytomegalovirus&#xD;
           reactivation.&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I, dose-escalation study of alemtuzumab followed by an&#xD;
      open-label, phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin&#xD;
           hydrochloride IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Patients&#xD;
           also receive alemtuzumab subcutaneously (SC) on day 1 OR on days 1, 8, and 15. Treatment&#xD;
           repeats every 3 weeks for up to 8 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of alemtuzumab until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive CHOP chemotherapy and alemtuzumab (at the MTD determined in&#xD;
           phase I) as in phase I (on the most effective regimen).&#xD;
&#xD;
      Patients undergo blood collection at baseline, periodically during study treatment, and after&#xD;
      completion of study treatment for pharmacokinetics and other correlative studies. Samples are&#xD;
      examined for presence of cytomegalovirus antigen and by flow cytometry for B- and T-cell&#xD;
      quantification.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 84 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity as assessed by NCI Common Toxicity Criteria Version 3.0</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of alemtuzumab</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as assessed by clinical, radiologic, pathologic, and laboratory measurements</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of treatment on T- and B-cell reconstitution by flow cytometry at baseline and at 3, 6, and 12 months</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed aggressive peripheral T-cell non-Hodgkin's lymphoma (NHL),&#xD;
             including the following nodal or extranodal subtypes:&#xD;
&#xD;
               -  Nodal:&#xD;
&#xD;
                    -  Angioimmunoblastic lymphadenopathy&#xD;
&#xD;
                    -  ALK 1-negative anaplastic large cell NHL&#xD;
&#xD;
                    -  Peripheral T-cell lymphoma not otherwise specified&#xD;
&#xD;
               -  Extranodal:&#xD;
&#xD;
                    -  Hepatosplenic NHL&#xD;
&#xD;
                    -  Enteropathy-associated NHL&#xD;
&#xD;
                    -  Panniculitic NHL&#xD;
&#xD;
          -  Stage II-IV disease&#xD;
&#xD;
          -  Newly diagnosed, CD52+ disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No known CNS involvement with lymphoma&#xD;
&#xD;
          -  No nasal natural killer T-cell NHL&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 4 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm³*&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm³*&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL*&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT &lt; 2 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL*&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known hypersensitivity to any of the study drugs&#xD;
&#xD;
          -  No serious illnesses that would preclude compliance with study requirements&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No other preexisting immunodeficiency (e.g., post-organ transplant)&#xD;
&#xD;
          -  No other malignancy within the past 5 years except cervical carcinoma in situ or&#xD;
             nonmelanoma skin cancer NOTE: *Unless directly attributable to NHL&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
               -  Up to 7 days of prednisone preceding initiation of chemotherapy allowed&#xD;
&#xD;
          -  No other concurrent chemotherapy, radiotherapy, or immunotherapy&#xD;
&#xD;
          -  No other concurrent corticosteroids except dexamethasone used as an antiemetic for a&#xD;
             brief period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rena Buckstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Paul's Hospital at Providence Health Care - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>604-806-9656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graeme Fraser, MD, FRCPC</last_name>
      <phone>905-575-7820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Mangel, MD</last_name>
      <phone>519-685-8615</phone>
      <email>joy.mangel@lhsc.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre at Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rena Buckstein, MD</last_name>
      <phone>416-480-5847</phone>
      <email>rena.buckstein@sunnybrook.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael R. Crump, MD, FRCPC</last_name>
      <phone>416-946-4567</phone>
      <email>michael.crump@uhn.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>August 10, 2006</study_first_submitted>
  <study_first_submitted_qc>August 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

